Losartan to Improve Hip Microfracture
Biologically Regulated Marrow Stimulation by Blocking Fibrosis to Improve Cartilage Repair: A Randomized Double-Blind, Placebo-Controlled Study
Sponsor: Office of Naval Research (ONR)
Terminated
redesigned trial using another placebo controlled drug
Other Cartilage Damage trials with similar outcome
Listed as NCT04212650, this PHASE1/PHASE2 trial focuses on Cartilage Damage and Fibrosis and remains terminated or withdrawn. Sponsored by Office of Naval Research (ONR), it has been updated 9 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Nov 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Nov 2023 [monthly]
Terminated PHASE1_PHASE2
Status: Recruiting → Terminated
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 4 earlier versions
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2020 — Oct 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2020 — Jun 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2020 — Feb 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Office of Naval Research (ONR)
- Steadman Philippon Research Institute
- United States Department of Defense
For direct contact, visit the study record on ClinicalTrials.gov .